← All trials
NCT05123599
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 26, 2021
- Primary completion
- May 31, 2023
- Completion date
- Mar 7, 2024
- First posted
- Nov 17, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 23
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.